One of the most important shifts in global pharma is happening not in Boston or Basel but in Shanghai, Beijing, and Suzhou. Chinese biotech has transformed from the world’s contract manufacturer into a genuine engine of drug innovation, and Western pharma is racing to license its drugs, at a scale that would have seemed impossible five years ago. Here is what is driving this licensing wave, what it means for the industry, and the tensions running underneath it.
The scale of the shift
The numbers are staggering. Cross-border out-licensing of drugs from Chinese biotech companies surged to a record in 2025, reaching well over a hundred billion dollars in total deal value, roughly a tenfold increase in just a few years. China now accounts for something like a third of global pharmaceutical licensing activity, and a large and growing share of the drug candidates that Western companies are licensing originate there. This is not a blip; it reflects a deliberate, decade-long strategy to build a world-class biotech industry, and that strategy has come to fruition. China has moved from copying and manufacturing to originating novel medicines.
Why Western pharma is looking east
Two forces are pulling big pharma toward Chinese assets. The first is the patent cliff: many of the industry’s biggest drugs are losing exclusivity over the next several years, threatening enormous revenue, and internal research alone cannot fill the gap fast enough. The second is cost and speed: Chinese biotechs can discover and develop drugs faster and more cheaply than their Western counterparts, thanks to lower costs, a vast patient population that speeds clinical trials, and a regulatory system that has harmonized with international standards. For a Western company facing a revenue gap and cutting its own R&D budget, licensing a promising, de-risked drug from China is a capital-efficient alternative to building it in-house or paying for a full acquisition. Analysts have described it as acquiring innovation at a fraction of the usual cost.
What China is especially good at
Chinese biotechs have built particular strength in exactly the areas Western pharma most wants. They dominate licensing in antibody-drug conjugates, having perfected much of the underlying chemistry, and they are leaders in bispecific antibodies, with a Chinese-originated cancer immunotherapy among the most closely watched drugs in the world. They are advancing quickly in cell therapies for autoimmune disease, protein degraders, and obesity and metabolic drugs, including next-generation options. This concentration of strength in the industry’s hottest modalities is a big part of why the deals have accelerated: China has assets in precisely the categories where Western pipeline gaps are most acute.
The terms are changing too
As the quality of Chinese assets has become undeniable, the economics have shifted. The upfront payments in these deals have risen dramatically, more than tripling in a few years, as Chinese biotechs recognize the value of what they have and Western companies agree to pay for it. As one analyst put it, China is “no longer the bargain basement.” A notable innovation is the rise of the NewCo model, in which a Chinese biotech licenses an asset to a newly formed, venture-backed company built specifically around it, often retaining an equity stake and capturing more of the long-term upside than a simple licensing deal would provide. The structures are becoming more sophisticated as both sides get more experienced.
The tensions underneath
This boom is not without friction, and the tensions are real. On the policy side, US measures aimed at Chinese biotech and manufacturing providers, along with tariffs and broader geopolitical strain, have introduced genuine uncertainty, pushing companies to think harder about supply chains, data access, and contractual protections, and to build in flexibility in case the environment shifts. On the diligence side, Western companies licensing Chinese assets do extra work to verify that the clinical data meets international standards and that the manufacturing can transfer cleanly, since the stakes of getting it wrong on a cross-border deal are high. None of this has stopped the wave, deal flow has continued to rise even amid the tension, but it means the smartest players approach these deals with their eyes open to the political and technical risks as well as the opportunity.
The bottom line
The China licensing wave represents a historic rebalancing of where pharmaceutical innovation comes from. Driven by Western patent cliffs and Chinese speed and cost, and concentrated in the industry’s hottest modalities, it has made China an essential source of new medicines and a first stop for business development teams building oncology and immunology pipelines. Geopolitical and diligence challenges add real complexity, and the policy environment bears watching, but the underlying trend, China as a co-equal engine of global drug innovation, looks durable. For anyone trying to understand where the industry’s pipeline is coming from, the answer increasingly runs through China.
What it means for the rest of the industry
The China licensing wave is not just a China story; it is reshaping strategy for everyone in the industry, and its implications ripple outward. For Western biotechs, it is a double-edged development: Chinese companies are increasingly competitors for the same disease targets and modalities, raising the bar, but they are also potential partners and a source of assets, and the abundance of licensable Chinese innovation changes the calculus of what to build in-house versus license. For business development teams, China has become a mandatory stop, and BD professionals now routinely scout Chinese assets as a core part of building a pipeline, which requires new relationships, cultural fluency, and specialized diligence capabilities that many organizations are racing to develop. For investors, the trend has created new opportunities, including the venture-backed structures built specifically to license and develop Chinese assets, as well as new risks tied to the geopolitical and policy uncertainty surrounding the corridor. For patients, the wave ultimately means more drug candidates advancing globally, and potentially faster access to innovative therapies, though the full benefit depends on those assets succeeding in late-stage development and reaching approval. And for the global balance of pharmaceutical innovation, it marks a genuine shift toward a more multipolar world, in which world-class drug discovery happens in multiple regions rather than being concentrated in a few traditional hubs. How the policy tensions resolve, particularly the measures aimed at Chinese biotech and manufacturing, will shape how smoothly this integration proceeds, but the underlying reality, that China is now a central source of the industry’s future medicines, is one that every player, in every region, now has to build into its strategy.
The diligence that makes these deals work
For companies pursuing Chinese assets, the opportunity comes with a distinctive set of diligence requirements, and getting them right is what separates successful deals from costly ones. Because the assets are developed in a different regulatory and operational environment, acquirers do extra work to verify that the clinical data was generated to standards that will satisfy Western regulators, checking that trials followed international good-practice guidelines and that the underlying data is robust and portable. They scrutinize the manufacturing, confirming that production processes can transfer cleanly to other facilities without losing quality or running into intellectual-property complications, since a drug that cannot be manufactured to global standards outside China is far less valuable. They examine the intellectual property carefully, ensuring the rights are clear and defensible in the markets where the Western partner will operate. And, increasingly, they assess the geopolitical and supply-chain risks, building contractual protections and flexibility to guard against a shifting policy environment. This specialized diligence is more demanding than a standard domestic deal, which is why experienced advisors and a rigorous, China-specific evaluation process have become essential for anyone serious about licensing from the region. The wave of deals shows the risks are manageable with the right approach, but they are real, and the companies that do this diligence well are the ones capturing the opportunity without inheriting hidden problems.
To follow the deals, readouts, and policy developments shaping this trend as it evolves, the BioMed Nexus daily brief tracks it closely, and for related context, see our pieces on the ADC boom (a category China now dominates in licensing) and how out-licensing deals actually work.
Frequently asked questions
How big is the China biotech licensing wave?
Cross-border out-licensing of drugs from Chinese biotech companies surged to a record in 2025, reaching well over a hundred billion dollars in total deal value, roughly a tenfold increase in a few years. China now accounts for around a third of global pharmaceutical licensing activity, and a growing share of the drugs Western companies license originate there.
Why is Western pharma licensing drugs from China?
Two main reasons: looming patent cliffs threaten major revenue that internal research cannot replace fast enough, and Chinese biotechs can develop drugs faster and more cheaply thanks to lower costs, a large patient population that speeds trials, and a harmonized regulatory system. Licensing a de-risked Chinese asset is a capital-efficient alternative to building in-house or full acquisition.
What is the BIOSECURE Act's effect on China biotech deals?
US measures aimed at certain Chinese biotech and manufacturing providers, alongside tariffs and geopolitical tension, have introduced real uncertainty into cross-border partnerships. Companies are doing more diligence around supply chains, data access, technology transfer and contractual exit rights, and building in flexibility, though deal flow has continued to rise despite the tension.
